

1. [The impact of stigma on quality of life and liver disease burden among patients with nonalcoholic fatty liver disease.](#)
Younossi ZM, AlQahtani SA, Funuyet-Salas J, Romero-Gómez M, Yilmaz Y, Keklikkiran C, Alswat K, Yu ML, Liu CJ, Fan JG, Zheng MH, Burra P, Francque SM, Castera L, Schattenberg JM, Newsome PN, Allen AM, El-Kassas M, Treeprasertsuk S, Hameed S, Wai-Sun Wong V, Zelber-Sagi S, Takahashi H, Kawaguchi T, Castellanos Fernández MI, Duseja A, Arrese M, Rinella M, Singal AK, Gordon SC, Fuchs M, Eskridge W, Alkhouri N, Cusi K, Loomba R, Ranagan J, Kautz A, Ong JP, Kugelmas M, Eguchi Y, Diago M, Gerber L, Lam B, Fornaresio L, Nader F, Spearman CW, Roberts SK, Chan WK, Silva M, Racila A, Golabi P, Ananchuensook P, Henry L, Stepanova M, Carrieri P, Lazarus JV; Global NASH Council. *JHEP Rep.* 2024 Mar 12;6(7):101066. doi: 10.1016/j.jhepr.2024.101066. eCollection 2024 Jul.
2. [Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease.](#)
Younossi ZM, Alqahtani SA, Alswat K, Yilmaz Y, Keklikkiran C, Funuyet-Salas J, Romero-Gómez M, Fan JG, Zheng MH, El-Kassas M, Castera L, Liu CJ, Wai-Sun Wong V, Zelber-Sagi S, Allen AM, Lam B, Treeprasertsuk S, Hameed S, Takahashi H, Kawaguchi T, Schattenberg JM, Duseja A, Newsome PN, Francque S, Spearman CW, Castellanos Fernández MI, Burra P, Roberts SK, Chan WK, Arrese M, Silva M, Rinella M, Singal AK, Gordon S, Fuchs M, Alkhouri N, Cusi K, Loomba R, Ranagan J, Eskridge W, Kautz A, Ong JP, Kugelmas M, Eguchi Y, Diago M, Yu ML, Gerber L, Fornaresio L, Nader F, Henry L, Racila A, Golabi P, Stepanova M, Carrieri P, Lazarus JV; Global NASH Council. *J Hepatol.* 2024 Mar;80(3):419-430. doi: 10.1016/j.jhep.2023.11.004. Epub 2023 Nov 18.
3. [Improving Outcomes in Hepatorenal Syndrome-Acute Kidney Injury With Early Diagnoses and Implementation of Approved Treatment Regimens.](#)
Pyrasopoulos NT, Bernstein D, Kugelmas M, Owen EJ, Reddy KR, Reau N, Saab S, Wadei HM. *Gastroenterol Hepatol (N Y).* 2023 Dec;19(12 Suppl 7):3-13.

4. [Expert perspectives for the pharmacist on facilitating and improving the use of albumin in cirrhosis.](#)
Kugelmas M, Loftus M, Owen EJ, Wadei H, Saab S.
Am J Health Syst Pharm. 2023 Jun 22;80(13):806-817. doi:
10.1093/ajhp/zxad070.
5. [The use of current knowledge and non-invasive testing modalities for predicting at-risk non-alcoholic steatohepatitis and assessing fibrosis.](#)
Kugelmas M, Nouredin M, Gunn N, Brown K, Younossi Z, Abdelmalek M, Alkhouri N.
Liver Int. 2023 May;43(5):964-974. doi: 10.1111/liv.15555. Epub 2023 Mar 27.
6. [Liver Cirrhosis Increases the Risk of Developing Advanced Colon Polyps.](#)
Kugelmas M, Zapata I, Tawil J, Pessetto A, Taglienti M, Kugelmas M.
Dig Dis Sci. 2023 Mar;68(3):931-938. doi: 10.1007/s10620-022-07561-1.
Epub 2022 Jun 7.
7. [Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis \(NASH\)/ Non-Alcoholic Fatty Liver Disease \(NAFLD\) Registry.](#)
Younossi ZM, Yilmaz Y, Yu ML, Wai-Sun Wong V, Fernandez MC, Isakov VA, Duseja AK, Mendez-Sanchez N, Eguchi Y, Bugianesi E, Burra P, George J, Fan JG, Papatheodoridis GV, Chan WK, Alswat K, Saeed HS, Singal AK, Romero-Gomez M, Gordon SC, Roberts SK, El Kassas M, Kugelmas M, Ong JP, Alqahtani S, Ziayee M, Lam B, Younossi I, Racila A, Henry L, Stepanova M; Global NASH Council.
Clin Gastroenterol Hepatol. 2022 Oct;20(10):2296-2306.e6. doi:
10.1016/j.cgh.2021.11.004. Epub 2021 Nov 9.

8. [A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver Disease.](#)
Younossi ZM, Ong JP, Takahashi H, Yilmaz Y, Eguc Hi Y, El Kassas M, Buti M, Diago M, Zheng MH, Fan JG, Yu ML, Wai-Sun Wong V, Alswat K, Chan WK, Mendez-Sanchez N, Burra P, Bugianesi E, Duseja AK, George J, Papatheodoridis GV, Saeed H, Castera L, Arrese M, Kugelmas M, Romero-Gomez M, Alqahtani S, Ziayee M, Lam B, Younossi I, Racila A, Henry L, Stepanova M; Global Nonalcoholic Steatohepatitis Council. *Clin Gastroenterol Hepatol.* 2022 Jun;20(6):e1456-e1468. doi: 10.1016/j.cgh.2021.06.048. Epub 2021 Jul 3.
9. [The Current Management of Hepatorenal Syndrome-Acute Kidney Injury in the United States and the Potential of Terlipressin.](#)
Flamm SL, Brown K, Wadei HM, Brown RS Jr, Kugelmas M, Samaniego-Picota M, Burra P, Poordad F, Saab S. *Liver Transpl.* 2021 Aug;27(8):1191-1202. doi: 10.1002/lt.26072. Epub 2021 Jul 14.
10. [Treatment Options for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing a Scheduled Procedure.](#)
Saab S, Bernstein D, Hassanein T, Kugelmas M, Kwo P. *J Clin Gastroenterol.* 2020 Jul;54(6):503-511. doi: 10.1097/MCG.0000000000001338.
11. [Financial Compensation For Hepatologists in Different Practice Settings.](#)
Shiffman ML, Sussman NL, Ravendhran N, Ditmyer M, Kowdley KV, Kugelmas M. *Hepatology.* 2019 Jun;69(6):2664-2671. doi: 10.1002/hep.30488. Epub 2019 Mar 12.
12. [Prospects for US-Cuba Cooperation in Gastroenterology, Hepatology and Liver Transplantation.](#)
Castellanos-Fernández MI, Infante-Velázquez M, Arús-Soler E, Kugelmas M, Bataller R, Villamil-Martínez R, Dorta-Guridi Z, Ruenes-Domenech C. *MEDICC Rev.* 2018 Apr;20(2):54-58. doi: 10.37757/MR2018.V20.N2.12.

13. [NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.](#)
Harrison SA, Rinella ME, Abdelmalek MF, Trotter JF, Paredes AH, Arnold HL, Kugelmas M, Bashir MR, Jaros MJ, Ling L, Rossi SJ, DePaoli AM, Loomba R.
Lancet. 2018 Mar 24;391(10126):1174-1185. doi: 10.1016/S0140-6736(18)30474-4. Epub 2018 Mar 5.
14. [Extrahepatic Benefits Achieved With Sustained Virologic Response in Patients With Hepatitis C Virus Infection.](#)
Kugelmas M.
Gastroenterol Hepatol (N Y). 2017 Sep;13(9):553-555.
15. [Hepatitis C Point-of-Care Screening in Retail Pharmacies in the United States.](#)
Kugelmas M, Pedicone LD, Lio I, Simon S, Pietrandoni G.
Gastroenterol Hepatol (N Y). 2017 Feb;13(2):98-104.
16. [The scope of hepatology practice outside the traditional academic medical center.](#)
Kugelmas M, Shiffman M.
Clin Liver Dis (Hoboken). 2016 Nov 30;8(5):117-118. doi: 10.1002/cld.584. eCollection 2016 Nov.
17. [Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study \(OPTIMIST-2\).](#)
Lawitz E, Matusow G, DeJesus E, Yoshida EM, Felizarta F, Ghalib R, Godofsky E, Herring RW, Poleyndard G, Sheikh A, Tobias H, Kugelmas M, Kalmeijer R, Peeters M, Lenz O, Fevery B, De La Rosa G, Scott J, Sinha R, Witek J.
Hepatology. 2016 Aug;64(2):360-9. doi: 10.1002/hep.28422. Epub 2016 Feb 19.

18. [The impact of an educational program on HCV patient outcomes using boceprevir in community practices \(OPTIMAL trial\).](#)
Poordad F, Rustgi V, Brown RS Jr, Patel V, Kugelmas M, Regenstein F, Balart L, LaBrecque D, Brown K, Avila M, Biederman M, Freed G, Smith R, Bernstein M, Arnold H, Cahan J, Fink S, Katkov W, Massoumi H, Harrison S.
Therap Adv Gastroenterol. 2015 Sep;8(5):263-9. doi: 10.1177/1756283X15588876.
19. [Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders.](#)
Jensen D, Sherman KE, Hézode C, Pol S, Zeuzem S, de Ledinghen V, Tran A, Elkhatab M, Younes ZH, Kugelmas M, Mauss S, Everson G, Luketic V, Vierling J, Serfaty L, Brunetto M, Heo J, Bernstein D, McPhee F, Hennicken D, Mendez P, Hughes E, Noviello S; HALLMARK-QUAD Study Team.
J Hepatol. 2015 Jul;63(1):30-7. doi: 10.1016/j.jhep.2015.02.018. Epub 2015 Feb 19.
20. [Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir \(MK-5172\) and elbasvir \(MK-8742\) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection \(C-WORTHY\): a randomised, open-label phase 2 trial.](#)
Sulkowski M, Hezode C, Gerstoft J, Vierling JM, Mallolas J, Pol S, Kugelmas M, Murillo A, Weis N, Nahass R, Shibolet O, Serfaty L, Bourliere M, DeJesus E, Zuckerman E, Dutko F, Shaughnessy M, Hwang P, Howe AY, Wahl J, Robertson M, Barr E, Haber B.
Lancet. 2015 Mar 21;385(9973):1087-97. doi: 10.1016/S0140-6736(14)61793-1. Epub 2014 Nov 11.
21. [Diagnosis of pancreatic duct-portal vein fistula; a case report and review of the literature.](#)
Brown A, Malden E, Kugelmas M, Kortz E.
J Radiol Case Rep. 2014 Mar 1;8(3):31-8. doi: 10.3941/jrcr.v8i3.1552. eCollection 2014 Mar.

22. [The impact of hepatitis C burden: an evidence-based approach.](#)
Younossi ZM, Kanwal F, Saab S, Brown KA, El-Serag HB, Kim WR, Ahmed A, Kugelmas M, Gordon SC.
Aliment Pharmacol Ther. 2014 Mar;39(5):518-31. doi: 10.1111/apt.12625.
Epub 2014 Jan 26.

23. [African americans are less likely to have clearance of hepatitis C virus infection: the findings from recent U.S. population data.](#)
Mir HM, Stepanova M, Afendy M, Kugelmas M, Younossi ZM.
J Clin Gastroenterol. 2012 Sep;46(8):e62-5. doi:
10.1097/MCG.0b013e318238352b.

24. [Using pegylated interferon and ribavirin to treat patients with chronic hepatitis C.](#)
Ward RP, Kugelmas M.
Am Fam Physician. 2005 Aug 15;72(4):655-62.

25. [Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy.](#)
Everson GT, Trotter J, Forman L, Kugelmas M, Halprin A, Fey B, Ray C.
Hepatology. 2005 Aug;42(2):255-62. doi: 10.1002/hep.20793.

26. [Treatment of Budd-Chiari syndrome in a liver transplant unit, the role of transjugular intrahepatic porto-systemic shunt and liver transplantation.](#)
Attwell A, Ludkowski M, Nash R, Kugelmas M.
Aliment Pharmacol Ther. 2004 Oct 15;20(8):867-73. doi: 10.1111/j.1365-2036.2004.02190.x.

27. [Liver biopsy.](#)
Kugelmas M.
Am J Gastroenterol. 2004 Aug;99(8):1416-7. doi: 10.1111/j.1572-0241.2004.40738.x.

28. [Hepatic artery chemoembolization for hepatocellular carcinoma in patients listed for liver transplantation.](#)
Hayashi PH, Ludkowski M, Forman LM, Osgood M, Johnson S, Kugelmas M, Trotter JF, Bak T, Wachs M, Kam I, Durham J, Everson GT. *Am J Transplant.* 2004 May;4(5):782-7. doi: 10.1111/j.1600-6143.2004.00413.x.

29. [Management of hepatitis C: evaluating suitability for drug therapy.](#)
Ward RP, Kugelmas M, Libsch KD. *Am Fam Physician.* 2004 Mar 15;69(6):1429-36.

30. [Impact of pretransplant diagnosis of hepatocellular carcinoma on cadveric liver allocation in the era of MELD.](#)
Hayashi PH, Trotter JF, Forman L, Kugelmas M, Steinberg T, Russ P, Wachs M, Bak T, Kam I, Everson GT. *Liver Transpl.* 2004 Jan;10(1):42-8. doi: 10.1002/lt.20020.

31. [Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection.](#)
Kugelmas M, Osgood MJ, Trotter JF, Bak T, Wachs M, Forman L, Kam I, Everson GT. *Liver Transpl.* 2003 Nov;9(11):1159-65. doi: 10.1053/jlts.2003.50233.

32. [Immunosuppression in liver transplantation.](#)
Everson GT, Trotter JF, Kugelmas M, Forman L. *Minerva Chir.* 2003 Oct;58(5):725-40.

33. [Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E.](#)
Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ. *Hepatology.* 2003 Aug;38(2):413-9. doi: 10.1053/jhep.2003.50316.

34. [Model for End-Stage Liver Disease score does not predict patient or graft survival in living donor liver transplant recipients.](#)
Hayashi PH, Forman L, Steinberg T, Bak T, Wachs M, Kugelmas M, Everson GT, Kam I, Trotter JF.
Liver Transpl. 2003 Jul;9(7):737-40. doi: 10.1053/jlts.2003.50122.
35. [Different immunosuppressive regimens and recurrence of primary sclerosing cholangitis after liver transplantation.](#)
Kugelmas M, Spiegelman P, Osgood MJ, Young DA, Trotter JF, Steinberg T, Wachs ME, Bak T, Kam I, Everson GT.
Liver Transpl. 2003 Jul;9(7):727-32. doi: 10.1053/jlts.2003.50143.
36. [Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications.](#)
Dunkelberg JC, Trotter JF, Wachs M, Bak T, Kugelmas M, Steinberg T, Everson GT, Kam I.
Liver Transpl. 2003 May;9(5):463-8. doi: 10.1053/jlts.2003.50079.
37. [Chronic mucoid Pseudomonas aeruginosa cholangitis complicating ERCP in a CF patient.](#)
Wallick K, Dickinson M, James DS, Kugelmas M, Madinger N, Rodman D.
J Cyst Fibros. 2002 Jun;1(2):99-101. doi: 10.1016/s1569-1993(02)00036-x.
38. [Living donor liver transplant recipients achieve relatively higher immunosuppressant blood levels than cadaveric recipients.](#)
Trotter JF, Stolpman N, Wachs M, Bak T, Kugelmas M, Kam I, Everson GT.
Liver Transpl. 2002 Mar;8(3):212-8. doi: 10.1053/jlts.2002.31346.
39. [Adult-to-adult living donor liver transplantation using right-lobe grafts: results and lessons learned from a single-center experience.](#)
Bak T, Wachs M, Trotter J, Everson G, Trouillot T, Kugelmas M, Steinberg T, Kam I.
Liver Transpl. 2001 Aug;7(8):680-6. doi: 10.1053/jlts.2001.26509.

40. [Endoscopic localization and management of colonic bleeding in patients with portal hypertension.](#)
Bernard AC, Hagihara PF, Burke VJ, Kugelmas M.
Surg Laparosc Endosc Percutan Tech. 2001 Jun;11(3):195-8.
41. [Right hepatic lobe donation for living donor liver transplantation: impact on donor quality of life.](#)
Trotter JF, Talamantes M, McClure M, Wachs M, Bak T, Trouillot T, Kugelmas M, Everson GT, Kam I.
Liver Transpl. 2001 Jun;7(6):485-93. doi: 10.1053/jlts.2001.24646.
42. [Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus.](#)
Trotter JF, Wachs ME, Trouillot TE, Bak T, Kugelmas M, Kam I, Everson G.
Liver Transpl. 2001 May;7(5):401-8. doi: 10.1053/jlts.2001.23916.
43. [HCV RNA values.](#)
Kugelmas M.
Dig Dis Sci. 2000 Dec;45(12):2428. doi: 10.1023/a:1005676000338.
44. [Cirrhosis in Turner's syndrome: case report and literature review.](#)
Idilman R, De Maria N, Colantoni A, Kugelmas M, Van Thiel DH.
Eur J Gastroenterol Hepatol. 2000 Jun;12(6):707-9.
45. [Preliminary observation: oral zinc sulfate replacement is effective in treating muscle cramps in cirrhotic patients.](#)
Kugelmas M.
J Am Coll Nutr. 2000 Feb;19(1):13-5. doi: 10.1080/07315724.2000.10718908.

46. [Cytokines in alcoholic liver disease.](#)
McClain CJ, Barve S, Deaciuc I, Kugelmas M, Hill D.
Semin Liver Dis. 1999;19(2):205-19. doi: 10.1055/s-2007-1007110.
47. [Budd-Chiari syndrome. Treatment options and the value of liver transplantation.](#)
Kugelmas M.
Hepatogastroenterology. 1998 Sep-Oct;45(23):1381-6.
48. [Immunosuppressive drug-induced leukoencephalopathy in patients with liver transplant.](#)
Idilman R, De Maria N, Kugelmas M, Colantoni A, Van Thiel DH.
Eur J Gastroenterol Hepatol. 1998 May;10(5):433-6. doi:
10.1097/00042737-199805000-00015.
49. [Alcoholic liver disease. Treatment strategies for the potentially reversible stages.](#)
Hill DB, Kugelmas M.
Postgrad Med. 1998 Apr;103(4):261-4, 267-8, 273-5. doi:
10.3810/pgm.1998.04.462.
50. [Nontraumatic abdominal pain.](#)
Kelso LA, Kugelmas M.
AACN Clin Issues. 1997 Aug;8(3):437-48. doi: 10.1097/00044067-
199708000-00012.
51. [Chronic alcohol consumption intensifies caerulein-induced acute pancreatitis in the rat.](#)
Quon MG, Kugelmas M, Wisner JR Jr, Chandrasoma P, Valenzuela JE.
Int J Pancreatol. 1992 Aug;12(1):31-9. doi: 10.1007/BF02927068.